Last reviewed · How we verify

NCT03540797

Myeloid-derived Suppressor Cells in Sepsis

Status unknown Last updated 31 May 2018
What this trial tests

trial in Sepsis in 125 participants. Status unknown.

Timeline
1 July 2015
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorChung Fu-Tsai
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment125
Start date1 July 2015
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across Taiwan

Conditions studied

Sponsor

Chung Fu-Tsai

Who can join

Adults 18 to 99, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed for septic patients, to isolate MDSCs and the correlation of prognosis of sepsis. The purpose of this study hopes to explore the phenomenon and possible mechanisms of MDSCs in patients with severe sepsis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03540797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing